BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SPY003 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SPY003\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07012395-28@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SPY003: Phase 2 readout est. (NCT07012395)
DESCRIPTION:SPY003\, phase 2\, Ulcerative Colitis.\nStudy: A Study of Long-
 acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerat
 ive Colitis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy003#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07012395
URL:https://assetmemo.bio/drug/spy003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652294-28@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:SPY003: Phase 2 readout est. (NCT07652294)
DESCRIPTION:SPY003\, phase 2\, Ulcerative Colitis.\nStudy: Long-term Safety
  and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations
  for IBD\nEstimated primary completion: 2 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/spy003#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07652294
URL:https://assetmemo.bio/drug/spy003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
